Audit export: Halden Therapeutics AG

Sample, fictional data. Halden Therapeutics AG is a fictional organization. The evidence is written for this sample. The shape of the export is not fictional. Machine-readable versions: halden-audit-export.json and halden-audit-export.csv at reliablecontext.com/samples.

Record	halden-therapeutics-ag
Kind / anchor	Company / haldentx.com
Record opened	2025-10-09
Export as of	2026-03-12
Reader	Research analyst, public-sources clearance

Lead program

property	`lead_program`
status	**cited**
value	HLD-204
excerpt	“Following the January reprioritisation, HLD-204 is our lead candidate and our principal development priority.”
source	Corporate presentation, February 2026
locator	slide 4
observed	2026-03-11 (date the source was read)
entered	2026-03-11 (date the value entered the record)
chosen over	HLD-118, haldentx.com/pipeline, page not revised since August 2025 (read 2026-03-11). A dated presentation outranks an unrevised web page.
reader clearance	open; no source licence restricts this value

Mechanism

property	`mechanism`
status	**blocked**
source	Journal of Medicinal Chemistry 69(4), subscription
locator	doi:10.1021/acs.jmedchem.5c02211
attempted	2026-03-12
note	A characterisation of the target exists in a journal this reader is not cleared to read. The article has not been retrieved and nothing from it is asserted here. The public pipeline page calls HLD-204 a pan-RAS inhibitor, which the record holds as a competing claim rather than an answer, because the page names no assay.
reader clearance	Licensed source, not permitted for reader clearance public-sources.

Development phase

property	`development_phase`
status	**cited**
value	Phase 2
excerpt	“This open-label Phase 2 study of HLD-204 in previously treated metastatic pancreatic adenocarcinoma is currently recruiting.”
source	ClinicalTrials.gov NCT06712233, record version 9
locator	clinicaltrials.gov/study/NCT06712233
observed	2026-03-11 (date the source was read)
entered	2026-03-11 (date the value entered the record)
chosen over	Phase 1/2, Company press release, 14 January 2026 (read 2026-03-11). The registry record outranks a press release about it.
reader clearance	open; no source licence restricts this value

Headquarters

property	`headquarters`
status	**cited**
value	Basel, Switzerland
excerpt	“Halden Therapeutics AG maintains its registered office at Aeschenvorstadt 24, 4051 Basel.”
source	Commercial Register of Basel-Stadt, extract CHE-417.882.106
locator	page 1
observed	2026-03-12 (date the source was read)
entered	2026-03-12 (date the value entered the record)
chosen over	Cambridge, Massachusetts, Press release boilerplate, 3 February 2025 (read 2025-10-09). A register extract outranks press-release boilerplate. Zug, Switzerland, Delegate listing, BIO-Europe 2025 (read 2025-11-22). A delegate listing is not an assertion about the office.
reader clearance	open; no source licence restricts this value

Phase 2 readout date

property	`phase_2_readout_date`
status	**not found**
searched	ClinicalTrials.gov NCT06712233, record version 9, 2026-03-11: estimated primary completion only Corporate presentation, February 2026, 2026-03-11: the phrase in due course Investor call transcript, 26 February 2026, 2026-03-12: question asked, not answered Two conference abstracts, AACR 2026, 2026-03-13: Phase 1 data only
note	No source we hold states a readout date. The registry's estimated primary completion is a different quantity and is not reported as one.
reader clearance	open